Patient enrolment details CKDOD registry

Similar documents
Supplementary Appendix

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Diabetes and Hypertension

Supplementary Appendix

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Management of early chronic kidney disease

Condition/Procedure Measure Compliance Criteria Reference Attribution Method

Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012

Renal Protection Staying on Target

Chemistry Reference Ranges and Critical Values

Chemistry Reference Ranges and Critical Values

ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour

QUICK REFERENCE FOR HEALTHCARE PROVIDERS

CKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College

i. Where is the participant seen?

The contractor establishes and maintains a register of patients with AF

Diabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy

DIABETES AND YOUR KIDNEYS

Dr. Liliana Garneata Assistant Professor of Nephrology Dr Carol Davila Teaching Hospital of Nephrology, Bucharest, Romania

Clinical Recommendations: Patients with Periodontitis

Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus

CHRONIC KIDNEY FAILURE

How Low Do We Go? Update on Hypertension

Cardiac Pathophysiology

Adult Diabetes Clinician Guide NOVEMBER 2017

RENAL FAILURE IN CHILDREN Dr. Mai Mohamed Elhassan Assistant Professor Jazan University

hypertension Head of prevention and control of CVD disease office Ministry of heath

CKDinform: A PCP s Guide to CKD Detection and Delaying Progression

Chronic kidney disease in cats

egfr > 50 (n = 13,916)

Chronic Kidney Disease. Basics of CKD Terms Diagnosis Management

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

HIV AND CHRONIC KIDNEY DISEASE. Understanding GFR

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009

POTENTIAL LINKAGES BETWEEN THE QUALITY AND OUTCOMES FRAMEWORK (QOF) AND THE NHS HEALTH CHECK

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care

Management of Hypertension

Metabolic Syndrome and Chronic Kidney Disease

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Chronic Kidney Disease

SUPPLEMENTAL MATERIAL

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Multiphasic Blood Analysis

Stages of Chronic Kidney Disease (CKD)

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

>4000 mg/dl (=20000/(500/100)) >615 mmol/l (=20000/(65*0.5))

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Taking Care of Your Kidneys

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease

Variable Included. Excluded. Included. Excluded

Management of High Blood Pressure in Adults

ADPedKD: detailed description of data which will be collected in this registry

Ministry of Health, Labour and Welfare Prevention of Kidney Disease Progression Action Plan

Tables of Normal Values (As of February 2005)

PROs for Drug Development. Melanie Blank, MD

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Rosnawati Yahya. Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng.

14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE

Evolve180 / Ideal Northwest Health Profile

Difficult to Treat Hypertension

DIABETES AND CHRONIC KIDNEY DISEASE

Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS

17/18 Threshold 18/19 Points 18/19. Points NO CHANGE NO CHANGE NO CHANGE

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya

MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers

STARS SYSTEM 5 CATEGORIES

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

Applying clinical guidelines treating and managing CKD

Case Study: Chronic Kidney Disease

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

Supplementary Online Content

SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND CLINICAL

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Launch Meeting 3 rd April 2014, Lucas House, Birmingham

Lab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.

CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER. The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2

Elevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC

Your health is a crucial aspect of your life. That s why the Yakima Heart Center offers this booklet; to help you identify the numbers that affect

TEMPLATE CASE REPORT FORM. Rapid Response Pharmacovigilance in Palliative Care

Clinician Blood Panel Results

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

in CKD Patients Associate Professorr of Medicine Iran University of Medical Sciences

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

SITA 100 mg (n = 378)

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

What s In the New Hypertension Guidelines?

Non-protein nitrogenous substances (NPN)

THE KIDNEY AND SLE LUPUS NEPHRITIS

ANNEX FORM TO EXAMINE THE CAUSES OF ESRD I IDENTIFICATION. 1 Record number (patient chart) Name. 1.1 Date of birth / / 1.2 Sex:

APPLICATION FORM CHRONIC MEDICINE BENEFIT 2019

ARE YOU AT INCREASED RISK FOR CHRONIC KIDNEY DISEASE?

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong

Transcription:

Patient enrolment details CKDOD registry Personal Information Date of enrolment D D Date of birth D D Gender Descent Height cm m History of smoking Y N U Date of first diagnosis of CKD D D Primary Cause of CKD Diabetes mellitus Hypertension Glomerulonephritis Inherited disease (eg polycystic kidney disease) alformations / birth defects Autoimmune disorder (eg lupus) Obstructions (kidney stones, tumours, enlarged prostate gland) Infections Toxic chemicals Injury or trauma Reflux nephropathy Drug- or medication-induced kidney problems Unknown Y=Yes N=No U=Unknown Patient enrolment details - Page 1/1

General Information Date of visit D D Patient Details at Checkup Is the patient currently on dialysis? Y N U Body weight Waist circumference kg lb cm Is the patient pregnant? Y N U CKD-related hospitalisation since last visit? Y N U Primary diagnosis for hospitalisation Secondary diagnosis for hospitalisation Comorbidities Chronic metabolic acidosis (serum bicarbonate level below 22 mmol/l) Y N U AIDS (with clinical symptoms besides being HIV positive) Y N U Osteoporosis (only if patient is treated for osteoporosis) Y N U Denture (if yes, is it fitted or not?) Periodontal disease Y N U Connective tissue disease (eg rheumatoid arthritis) Y N U Cerebrovascular disease (stroke with mild or no residual or TIA) Y N U Dementia Y N U Hemiplegia (severe weakness of arm/leg on one side of the body) Y N U yocardial infarction (clinical event, not ECG changes only) Y N U Congestive heart failure (inability of the heart for sufficient pump action) Y N U Peripheral vascular disease (includes aortic aneurysm >= 6 cm) Y N U Chronic pulmonary disease Y N U Peptic ulcer disease Y N U Y=Yes N=No U=Unknown Progress form - Page 1/5

ild liver disease (without portal hypertension, includes chronic hepatitis) Y N U oderate or severe liver disease Y N U Diabetes without end-organ damage (excludes diet-controlled alone) Y N U Diabetes with end-organ damage Y N U (retinopathy, neuropathy, nephropathy, or or brittle diabetes) Nephrotic syndrome Y N U oderate to severe renal disease (CKD stage 3 to 5) Y N U Tumour without metastasis (check no if more than 5 y since diagnosis) Y N U etastatic solid tumour Y N U Leukaemia (acute or chronic) Y N U Lymphoma Y N U Inflammation Y N U uscle-wasting disease Y N U Dialysis Type of dialysis (none, HD, HDF, PD) Dialysis frequency per week When did dialysis start? D D What type of dialyser is used? Serum /Plasma Parameters Creatinine BUN (blood urea nitrogen) Sodium Potassium mg/dl μmol/l mmol/l meq/l mmol/l Total protein g/dl g/l Bicarbonate Uric acid meq/l mmol/l mg/dl μmol/l Y=Yes N=No U=Unknown Progress form - Page 2/5

Calcium mg/dl meq/l mmol/l Phosphate Hemoglobin g/dl g/l mmol/l CRP mg/l Total cholesterol mg/l mmol/l LDL cholesterol HDL cholesterol Triglycerides ALT (alanine aminotransferase) Urea Fasting blood glucose U/L HbA1c % ph Albumin g/dl Urinary Parameters Urine volume (in 24h) ml L Urea nitrogen (in 24h urine) g/24h mmol/24h Creatinine (in 24h urine) Urea (in 24h urine) Albumin (in 24h urine) mg/24h mmol/24h mg/24h mg/min g/24h mol/24h mg/24h mg/mmol mg Urea nitrogen (in spot urine) Protein (in spot urine) Creatinine (in spot urine) mg/dl mg/dl Albumin (in spot urine) mg/dl mg/mg urine-creatinine Proteinuria Y N U Y=Yes N=No U=Unknown Progress form - Page 3/5

Blood Pressure Systolic blood pressure Diastolic blood pressure mm Hg mm Hg Where / how was it measured? Centre At home Continuoulsy over 24 h edication Sulphonylurea compounds Y N U Thiazolidinediones / Glitazones Y N U Alphaglucosidaseinhibitor Y N U Biguanide Y N U Dipeptidyl peptidase IV inhibitors Y N U eglitinides Y N U Insulin Y N U SGLT2 inhibitor (sodium glucose transport protein inhibitor) Y N U Beta blockers Y N U ACEI (angiotensin converting enzyme inhibitors) Y N U Alpha receptor blockers Y N U Calcium antagonists Y N U ARB (angiotensin II receptor blockers) Y N U Loop diuretics Y N U Potassium sparing diuretics Y N U Thiazides Y N U Carbonic anhydrase inhibitors Y N U DRI (dopamine reuptake inhibitor) Y N U Phosphate binders Y N U Allopurinol Y N U Erythropoitein Y N U TC (traditional Chinese medicine) Y N U drugs Y=Yes N=No U=Unknown Progress form - Page 4/5

Dietary anagement Ketoanalogues (please specify) Ketoanalogues dosage tablets/day Number of ketoanalogue pills prescribed Date of last ketoanalogue pill prescription How many ketoanalogue pills does the patient still possess? If keto supplementation has been discontinued, please select the main reason: Further decline of egfr Lack of compliance Shift to RRT PEW (protein energy wasting) suspected? Y N U Type of protein restriction None VLPD (03-05 g/kg bw /d) LPD (06-08 g/kg bw /d) HPD (greater than 10 g /kg bw /d) Vegetarian? Y N U Followed up by a dietician? Y N U Using a nutritionary diary? Y N U How do you judge the patient s dietary compliance? (1=perfect; 5=not compliant) Daily amount of consumed calories Daily recommended calories (without ketoanalogues) Daily amount of consumed protein Daily recommended protein (without ketoanalogues) g /kg bw/day g /day g /kg bw/day g /day g /kg bw/day g /day g /kg bw/day g /day Y=Yes N=No U=Unknown Progress form - Page 5/5

Nutritional risk screening CKDOD registry Please use this form if PEW (protein energy wasting) is suspected Date of screening D D Table 1: Initial screening 1 Is BI below 205? Y N 2 Has the patient lost weight within the last 3 months? Y N 3 Has the patient had a reduced dietary intake in the last week? Y N 4 Is the patient severely ill? (eg in intensive therapy) Y N If the answer is Yes to any question, please perform the screening in Table 2 If the answer is No to all questions, the screening is finished Table 2: Final screening (please rate the impaired nutritional status and severity of disease and add both scores) Impaired nutritional status Normal nutritional status Weight loss more than 5% in 3 months and/or Food intake below 50 75% of normal requirement in preceding week Weight loss more than 5% in 2 months and/or BI 185-205 + impaired general condition and/or Food intake 25 50% of normal requirement in preceding week Weight loss more than 5% in 1 month (more than 15% in 3 months) and/or BI below 185 + impaired general condition and/or Food intake 0 25% of normal requirement in preceding week Absent Score 0 ild Score 1 oderate Score 2 Severe Score 3 Score Age: if 70 years or older, add 1 to total score above Severity of disease ( increase in requirements) Normal nutritional requirements Hip fracture and/or Chronic patients, in particular with acute complications: cirrhosis, COPD and/or Chronic hemodialysis, diabetes, oncology ajor abdominal surgery and/or Stroke and/or Severe pneumonia, hematologic malignancy Head injury and/or Bone marrow transplantation and/or Intensive care patients (APACHE > 10) = Total score: = Age-adjusted score: Absent Score 0 ild Score 1 oderate Score 2 Severe Score 3 Score Score 3 or higher: The patient is nutritionally at risk and a nutritional care plan is initiated Score below 3: Weekly re-screening of the patient If the patient eg is scheduled for a major operation, a preventive nutritional care plan is considered to avoid the associated risk status odified from Kondrup et al Clinical Nutrition 2003; 22: 415-421 Y=Yes N=No Nutritional risk screening - Page 1/1

Quality of life form CKDOD registry Quality of Life (please refer to the COOP-Charts for details) All questions refer to the past 4 weeks Hardest physical activity possible for at least 2 minutes Very heavy (1) Heavy (2) oderate (3) Light (4) Very light (5) Emotional problems Not at all (1) Slightly (2) oderately (3) Quite a bit (4) Extremely (5) Difficulty with usual activities No difficulty at all (1) A little bit of difficulty (2) Some difficulty (3) uch difficulty (4) Could not do (5) Limitations of social activities No (1) Yes, slightly (2) Yes, moderately (3) Yes, a lot (4) Yes, extremely (5) Pain No pain (1) Very mild pain (2) ild pain (3) oderate pain (4) Severe pain (5) Change in health compared to 4 weeks ago uch better (1) A little better (2) About the same (3) A little worse (4) uch worse (5) Overall health Excellent (1) Very good (2) Good (3) Fair (4) Poor (5) Social support Yes, as much as patient wanted (1) Yes, quite a bit (2) Yes, some (3) Yes, a little (4) No, not at all (5) Quality of life Very well (1) Pretty good (2) Good & bad parts about equal (3) Pretty bad (4) Very bad (5) Y=Yes N=No U=Unknown Quality of life form - Page 1/1

Loss to follow-up form CKDOD registry General Information Date of recording D D Reason for loss to follow-up Patient received kidney transplantation Patient moved Transferred to a colleague Patient died Complications No information If the patient died, please specify cause Cardiac disease Cerebrovascular disease Infection alignancy Renal failure Unknown Date of death D D If patient was lost to follow-up due to complications, please specify Loss to follow-up form - Page 1/1